Antibody Responses In Non-Severe SARS-CoV-2 Infections Are Driven By CD4+ T cells and Age.

SARS-CoV-2 infection causes a spectrum of clinical outcomes and diverse memory responses. Population studies indicate that viral neutralizing antibody responses are protective, but do not always develop post-infection. Other antiviral antibody effector functions, T-cell responses, or immunity to seasonal coronaviruses (OC43, 229E) have been implicated but not defined in all ages. Here, we identify that children and adult subjects generate polyfunctional antibodies to the spike protein after asymptomatic infection or mild disease, with some subjects developing cellular responses without seroconversion. Diversity in immunity was explained by two clusters distinguished by CD4+ T-cell cytokines, age, and antibodies to seasonal coronaviruses. Post-vaccination neutralizing responses were predicted by specific post-infection immune measures, including IL-2, spike-IgA, OC43-IgG1, 229E-IgM. We confirm a key role for CD4+ T cell cytokines in functionality of anti-spike antibodies, and show that antibody diversity is impacted by age, Th/Th2 cytokine biases, and antibody isotypes to SARS-CoV-2 and seasonal coronaviruses.

[1]  P. Moss The T cell immune response against SARS-CoV-2 , 2022, Nature Immunology.

[2]  A. Randolph,et al.  Immunology of SARS-CoV-2 infection in children , 2022, Nature Immunology.

[3]  Mark M. Davis,et al.  Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity , 2022, Science Translational Medicine.

[4]  E. L. Potter,et al.  Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues , 2022, bioRxiv.

[5]  F. Dentali,et al.  Mucosal immune response in BNT162b2 COVID-19 vaccine recipients , 2021, eBioMedicine.

[6]  Maureen A. McGargill,et al.  Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response , 2021, Cell Host & Microbe.

[7]  M. Davenport,et al.  Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis , 2021, The Lancet Microbe.

[8]  J. Klausner,et al.  Protective immunity after recovery from SARS-CoV-2 infection , 2021, The Lancet Infectious Diseases.

[9]  Carly A. Bobak,et al.  Boosting of Cross-Reactive Antibodies to Endemic Coronaviruses by SARS-CoV-2 Infection but not Vaccination with Stabilized Spike , 2021, medRxiv.

[10]  Hyeong Mi Kim,et al.  Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study , 2021, Science.

[11]  D. Lauffenburger,et al.  Early cross-coronavirus reactive signatures of humoral immunity against COVID-19 , 2021, Science Immunology.

[12]  J. Mascola,et al.  Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants , 2021, Science.

[13]  A. Lanzavecchia,et al.  Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients. , 2021, Science immunology.

[14]  E. Wherry,et al.  Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination , 2021, Immunity.

[15]  L. Poon,et al.  SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection , 2021, Nature Communications.

[16]  Sagar,et al.  Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine , 2021, Nature.

[17]  M. Lipsitch,et al.  Covid-19 Breakthrough Infections in Vaccinated Health Care Workers , 2021, The New England journal of medicine.

[18]  Fanfan Zeng,et al.  Over 1‐year duration and age difference of SARS‐CoV‐2 antibodies in convalescent COVID‐19 patients , 2021, Journal of medical virology.

[19]  C. Putensen,et al.  Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ T cell help , 2021, Cell Reports.

[20]  A. Iwasaki,et al.  Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2 , 2021, bioRxiv.

[21]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[22]  Kenneth G. C. Smith,et al.  Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease , 2021, Immunity.

[23]  R. Sanders,et al.  High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages , 2021, Science Translational Medicine.

[24]  C. Woods,et al.  Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents , 2021, medRxiv.

[25]  S. Kent,et al.  Systems serology detects functionally distinct coronavirus antibody features in children and elderly , 2021, Nature Communications.

[26]  Zhengming Chen,et al.  Association of Age With SARS-CoV-2 Antibody Response , 2021, JAMA network open.

[27]  Christopher J. Lyon,et al.  Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2 infection. , 2021, The Journal of clinical investigation.

[28]  L. Poon,et al.  Neutralizing antibody titres in SARS-CoV-2 infections , 2021, Nature communications.

[29]  C. Rice,et al.  Enhanced SARS-CoV-2 neutralization by dimeric IgA , 2020, Science Translational Medicine.

[30]  O. Schwartz,et al.  IgA dominates the early neutralizing antibody response to SARS-CoV-2 , 2020, Science Translational Medicine.

[31]  N. Kootstra,et al.  Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity , 2020, Science.

[32]  S. Mallal,et al.  Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases , 2020, bioRxiv.

[33]  D. Lauffenburger,et al.  Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[34]  C. Dutertre,et al.  Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection , 2020, bioRxiv.

[35]  E. Hod,et al.  Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum , 2020, Nature Immunology.

[36]  D. Lauffenburger,et al.  Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality , 2020, Cell.

[37]  J. Greenbaum,et al.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.

[38]  P. Sopp,et al.  Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 , 2020, Nature Immunology.

[39]  L. Carter,et al.  Functional SARS-CoV-2-specific immune memory persists after mild COVID-19 , 2020, medRxiv.

[40]  D. Weissman,et al.  D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization , 2020, Cell Host & Microbe.

[41]  Yang Wu,et al.  SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19 , 2020, Nature Communications.

[42]  Nichollas E. Scott,et al.  Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19 , 2020, Nature Medicine.

[43]  Harnish Mukesh Naik,et al.  Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population , 2020, medRxiv.

[44]  H. Karakuła-Juchnowicz,et al.  COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge , 2020, Journal of clinical medicine.

[45]  Ilya J. Finkelstein,et al.  Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes , 2020, bioRxiv.

[46]  Li Zhu,et al.  Correlation between viral RNA shedding and serum antibodies in individuals with coronavirus disease 2019 , 2020, Clinical Microbiology and Infection.

[47]  Christopher J. Lyon,et al.  Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 diagnosis , 2020, Biosensors and Bioelectronics.

[48]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[49]  Shenmin Zhang,et al.  Proinflammatory IgG Fc structures in patients with severe COVID-19 , 2020, Nature Immunology.

[50]  Trey Ideker,et al.  A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing , 2020, bioRxiv.

[51]  G. Alter,et al.  A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation☆ , 2019, Journal of immunological methods.

[52]  G. Alter,et al.  A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis , 2019, Journal of immunological methods.

[53]  D. Lauffenburger,et al.  Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement , 2018, Science Immunology.

[54]  K. McKinnon Multiparameter Conventional Flow Cytometry. , 2018, Methods in molecular biology.

[55]  P. Arner,et al.  Increased fat cell size: a major phenotype of subcutaneous white adipose tissue in non-obese individuals with type 2 diabetes , 2016, Diabetologia.

[56]  T. Kurosaki,et al.  Critical role of the IgM Fc receptor in IgM homeostasis, B-cell survival, and humoral immune responses , 2012, Proceedings of the National Academy of Sciences.

[57]  F. Wong,et al.  Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen‐reactive T cell responses: position statement of the T‐Cell Workshop Committee of the Immunology of Diabetes Society , 2011, Clinical and experimental immunology.

[58]  D. Irvine,et al.  A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. , 2010, Journal of immunological methods.

[59]  C. Nilsson,et al.  Optimal Blood Mononuclear Cell Isolation Procedures for Gamma Interferon Enzyme-Linked Immunospot Testing of Healthy Swedish and Tanzanian Subjects , 2008, Clinical and Vaccine Immunology.

[60]  F. Gage,et al.  Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. , 1996, Proceedings of the National Academy of Sciences of the United States of America.